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                                    During the last 10 years, there has been a huge increase in the under-
standing of many diseases, based on a revolution in the molecular 
sciences (  1  ,  2  ). This knowledge has inevitably fueled considerable 
hope in the potential to cure many serious diseases, such as cancer, 
HIV/AIDS, and heart disease. In cancer, for example, there has been 
a dramatic and unprecedented increase in the number of potential 
new anticancer therapies in recent years. In 2005, it was estimated 
that 1994 anticancer agents were in development, including 195, 389, 
and 122 in clinical phases 1, 2, and 3, respectively (  3  ). Many of these 
agents result from advances in our understanding of cell biology, in 
particular, intracellular signaling pathways, growth factors and their 
receptors, and increased knowledge of the human genome. A sub-
stantial proportion of the agents are aimed at the same few molecular 
targets, such as the epidermal growth factor receptor and vascular 
endothelial growth factor receptor (  4  ). 
  However, in a report in March 2004, the US Food and Drug 
Administration (FDA) (  5  ) identiﬁ  ed a slowdown, rather than the 
expected acceleration, in innovative medical therapies being approved 
and reaching patients. Three factors have been highlighted as being 
involved in this downturn: 1) the high costs of bringing a new prod-
uct to market, which is estimated to be of the order of US $1.2 bil-
lion or more (  3  ); 2) the fact that most new treatments are not 
effective  —  the FDA has estimated that only approximately 8% of 
therapies entering phase 1 trials reach the market (  5  ); and 3) changes 
in the regulatory requirements for licensing approval. 
  A consequence of this slowdown in approvals is the concern 
that the hoped-for advances in improving survival and quality of 
life in many major diseases may not materialize. This downturn 
has happened even though biomedical research spending has more 
than doubled in real terms in the private sector globally over the 
last 10 years (  5  ). There have also been increases in public sector 
research funding internationally. For example, in the United 
Kingdom, spending from all sources, private and public, on bio-
medical research and development increased by 14% in real terms 
between 1994 and 2000 (  6  ). 
  To respond to this slowdown, the FDA has called for new addi-
tions to the “product-development toolkit” to achieve reliable results 
more rapidly (  5  ). In this commentary, we present one approach that 
addresses this need. 
    Affiliations of authors  : MRC Clinical Trials Unit, London, UK (MKBP, MS, RL, 
RK, AMS, WQ, PR); Institute of Psychiatry, King  ’  s College London, London, 
UK (FMSB); NCIC Clinical Trials Group, Queen’s University, Kingston, 
Ontario, Canada (EE); School of Public Health and Health Professions, 
University at Buffalo, Buffalo, NY (MB); CR-UK Institute for Cancer Studies, 
University of Birmingham, Birmingham, UK (NJ); Fox Chase Cancer Center, 
Philadelphia, PA (MAB)  .     
    Correspondence to:   Mahesh K. B. Parmar, DPhil, MRC Clinical Trials Unit, 
222 Euston Road, London, NW1 2DA, UK (e-mail:   mp@ctu.mrc.ac.uk  ).   
      See   “Funding” and “Notes” following “References.”   
      DOI:   10.1093/jnci/djn267   
    © 2008 The Author(s).   
  This is an Open Access article distributed under the terms of the Creative Com  -
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/), which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
    COMMENTARY   
          Speeding up the Evaluation of New Agents in Cancer   
        Mahesh K  . B      .     Parmar      ,           Friederike   M.  -S      .     Barthel      ,           Matthew           Sydes      ,           Ruth           Langley      ,           Rick           Kaplan      ,           Elizabeth           Eisenhauer      ,           Mark           Brady      , 
          Nicholas           James      ,           Michael A.           Bookman      ,           Ann  -M      arie     Swart      ,           Wendi           Qian      ,           Patrick           Royston                                   
  Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of devel-
opment during the last 10 years, the number of new treatments that have been approved for patients has not increased as 
expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than 
current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simul-
taneously, the new design requires fewer patients. Three trials using this methodology are presented. 
  J Natl Cancer Inst 2008;100:  1204    –    1214     
    Principles 
  There are many steps in the process of developing and evaluating 
new therapies. Here, we discuss some critical components of this 
process and provide an impetus for an alternative approach. 
    Acknowledge that Phase 2 Trials, as Currently Conducted, 
Are Not a Sufficiently Good Screen for Identifying 
Potentially Effective Therapies 
  The very large proportion of the recent cost increases in drug devel-
opment and testing [estimated as a 55% increase in the last 5 years 
(  5  )] are accumulated during the phase 2 and 3 components of the 
process. Phase 3 trials represent 65%  –  75% of the costs of the clinical 
phase portion (  7  ). A critical decision point is the selection of therapies 
to enter larger-scale randomized testing in phase 3 trials. Phase 2 tri-
als are usually designed as a “screen” to assess whether there is suffi-
cient therapeutic activity and an acceptable toxicity profile to warrant 
further testing and development in larger scale randomized phase 3 
trials. There is, however, a distinction between phase 2 trials that use 
the new drug as a single agent and those that use the new drug in 
combination with current routine therapies. Although in both types 
of phase 2 trials the primary concerns are safety and toxicity, the two 
types of trials differ in their aims of assessing activity. Single-agent 
phase 2 trials are useful in assessing whether the agent has a minimum jnci.oxfordjournals.org    JNCI | Commentary 1205
level of activity that would warrant further investigation. In contrast, 
in phase 2 trials of combination therapy, activity data are difficult to 
interpret because there will be an unquantifiable response to the 
underlying therapy and no randomized comparison is made. 
Furthermore, the relationship between any potential improvements 
in response rate and longer-term outcome measures, such as overall 
survival, remains unclear. One of the major difficulties in assessing the 
need for a randomized phase 3 trial is the relatively poor evidence that 
is provided by the noncomparative nature of phase 2 combination 
therapy trials. Although randomized controlled phase 2 trials have 
been proposed (  8  ), these designs do not generally provide robust 
or reliable evidence on which to base a decision regarding further 
testing because there is no direct comparison between the new ther-
apy and the control group.   
    Accept that the Size of the Effect of Most New Therapies 
on Important Outcome Measures, Such As Overall and 
Disease-Specific Survival, Is Usually Modest 
  During the last 20 years, it has become apparent that improvements 
in survival provided by new cancer agents, when added to standard 
care, are generally modest (  9  ,  10  ). Two examples of this are as fol-
lows. In the first-line treatment of patients with metastatic colorectal 
cancer, the addition of the drug bevacizumab to oxaliplatin-based 
chemotherapy improved median survival from 19.9 to 21.3 months 
(hazard ratio [HR] = 0.89, 95% confidence interval [CI] = 0.7 to 
1.03) (  11  ). In patients with mesothelioma, the drug pemtrexed 
improved median survival from 9.3 to 12.1 months (HR = 0.77, 
estimated 95% CI = 0.61 to 0.96) when added to cisplatin-based 
therapy (  12  ).   
    Acknowledge That Only a Small Proportion of New 
Therapies Will Prove To Be Better Than Current 
Standard Therapies 
  The FDA report (  5  ) emphasizes that only 8% of new drugs that 
enter phase 1 trials actually reach the market. In cancer, Roberts et 
al. (  9  ) found that of the 208 antineoplastic agents brought into clini-
cal trials from 1975 to 1994, only 29 (14%) ultimately received 
FDA marketing approval. In a different setting, a review of the 
randomized controlled trials conducted by the Children’s Oncology 
Group in the United States (  13  ) showed that in terms of the trend 
of an effect, new treatments are as likely to appear inferior to stan-
dard treatments as they are to appear superior. 
  Kola and Landis (  14  ) reviewed the success rates of new agents 
for a range of diseases from the top 10 pharmaceutical companies 
during the period 1991  –  2000. Their results suggest that the suc-
cess rate in phase 2, which is estimated as the proportion of new 
agents going on to be tested in phase 3, is reasonably independent 
of disease and is estimated to be between 30% and 40%. The suc-
cess of phase 3 trials, which is deﬁ  ned as a positive result from the 
trial, varied more across diseases, from 40% in oncology to 75% 
in cardiovascular disease. On average, across all diseases about 
50% of phase 3 trials are successful and lead to a licensing applica-
tion. A 40%  –  50% success rate for randomized phase 3 trials in 
cancer may be considered too low because it is no better than toss-
ing a coin. The ﬁ  nal hurdle for new agents is the licensing stage, 
and on average, 70% of agents that made a licensing application 
received one.     
    A Partial Solution 
  Consideration of the first two principles given above has led to a 
proposal in some instances to bypass traditional phase 2 trials and 
to conduct large phase 3 trials as early as possible during the 
development and testing of new agents, often including many thou-
sands of patients to reliably detect modest differences. This 
approach is increasingly being used by both the pharmaceutical 
industry and the academic sector. For example, two large-scale 
randomized phase 3 studies testing the addition of gefitinib (Iressa) 
to chemotherapy in advanced non  –  small cell lung cancer (  15    –    17  ) 
were conducted with 1093 and 1037, patients recruited. These two 
trials were initiated after two phase 2 trials of single-agent gefitinib 
showed the activity of this agent in more advanced stages of the 
disease (  17  ,  18  ). None of the three randomized phase 3 trials showed 
an improvement in overall survival with gefitinib, despite having 
large numbers of events for the primary outcome. 
  Many thousands of large-scale trials will be required to test all 
the potential new agents and combinations of them with other 
drugs. This approach is clearly unrealistic in a reasonable time 
frame. Therefore, although this solution may provide reliable 
results about the value of a therapy in a particular setting, it does 
not provide an appropriate strategy to respond to the problem. In 
fact, performing large numbers of large-scale trials could actually 
exacerbate the problem because such trials can take up a large pro-
portion of the pool of patients with the disease and prevent poten-
tially better agents from being tested.   
    A New Strategy: Multi-Arm Multi-Stage 
Design 
  We therefore need other strategies in our toolkit to speed up the 
process of getting reliable answers. A strategy may be considered 
useful if it can satisfy the following principles: 1) it is better than 
separate single-arm phase 2 trials in deciding whether to continue 
testing a new treatment; 2) it will test many new promising treat-
ments at the same time so that the probability of finding a success-
ful new treatment is increased; 3) it has the potential to discontinue 
unpromising arms quickly and reliably; and 4) it bases major deci-
sions on randomized evidence. 
  One approach that addresses all of the above principles is the 
multi-arm multi-stage (MAMS) randomized trial. In this approach, 
several agents are assessed simultaneously against a single control 
group in a randomized fashion. In the early stages of the trial, each 
of the experimental arms is compared in a pairwise manner with 
the control arm using an “intermediate” outcome measure that is 
required to be related to the primary outcome measure but does 
not have to be a true “surrogate” outcome measure [for deﬁ  nitions 
of surrogacy see (  19  )]. Recruitment to experimental arms that do 
not show sufﬁ  cient promise with the intermediate outcome mea-
sures is discontinued. Recruitment to the control arm and to the 
promising experimental arms continues until sufﬁ  cient numbers of 
patients have been entered to assess the impact of the experimental 
treatments on the primary outcome measure. 
  A hypothetical example is a randomized trial with four experi-
mental arms and one control arm, run in two stages (  Figure 1  ). 
The intermediate and primary outcome measures are progression-
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number of intermediate outcome events have been observed in the 
control arm, a pairwise comparison is made between each experi-
mental arm and the control arm. If the observed effect size does 
not cross a predeﬁ  ned critical value, then consideration is given to 
not randomly assigning additional patients to that experimental 
arm. Accrual to the trial, however, continues while the analysis is 
conducted. After the analysis, patients continue to be randomly 
assigned to those experimental treatments that do cross the critical 
value and also to the control arm until the prespeciﬁ  ed number of 
events on the primary outcome measure have been observed. The 
predeﬁ  ned critical value depends on four components: 1) the null 
hypothesis for the intermediate outcome measure (usually taken to 
be no difference), 2) the alternative hypothesis for the intermediate 
outcome measure, 3) the probability of continuing to the next 
stage should the null hypothesis be true, and 4) the probability of 
continuing to the next stage should the alternative hypothesis be 
true. The critical value is calculated for each stage by considering 
whether we can reject the null hypothesis (at the level of the prob-
ability of continuing to the next stage should the null hypothesis 
be true). Technical details are given in (  20  ), and the practical speci-
ﬁ  cation of these parameters is displayed in the examples below.         
  A general explanation of an intermediate outcome measure used 
in this way is as follows. If there is no effect on the intermediate 
outcome measure (ie, if the null hypothesis is true), then it is very 
likely that there will be no effect on the primary outcome measure. 
The intermediate outcome measure is therefore required to have 
high negative predictive value. However, if the alternative hypoth-
esis is true for the intermediate outcome, this will not necessarily 
mean that the alternative hypothesis will be true for the primary 
outcome measure. There is no requirement for the intermediate 
outcome measure to have a high positive predictive value. In trials 
of cancer treatment, typical intermediate outcome measures might 
be progression-free survival or response to treatment and a typical 
primary outcome measure might be overall survival. Extension of 
this model to more than two stages is shown in the examples below. 
In the MAMS design, a randomized comparison is initiated as soon 
as possible, although there still remains a role for single-agent 
phase 2 trials to prioritize new therapies for feeding into MAMS 
trials (  Figure 2  ). One of the ﬁ  rst advantages of the MAMS design 
is that many new treatments are considered at once, involving 
fewer patients over a shorter time with reduced costs than assessing 
each of the agents in large-scale separate two-arm trials. The 
multi-arm nature also improves the likelihood of a “positive” trial. 
For example, if a two-arm phase 3 trial in oncology has a 40% 
chance of showing a “positive” result (  14  ), and if we assume that 
the probability of success of each of the new experimental arms in 
a MAMS trial is approximately independent, then for a ﬁ  ve-arm 
cancer trial with four new experimental therapies, the probability 
of at least one successful arm in the trial increases to 87%.         
  We are aware of three trials that have used the MAMS design. 
These are the Systemic Therapy in Advancing or Metastatic 
Prostate Cancer: Evaluation of Drug Efﬁ  cacy (STAMPEDE) trial 
(  21  ); a collaborative trial, GOG-182/ICON5 (23), involving the 
Gynecologic Oncology Group (GOG) and the International 
Collaborative Ovarian Neoplasm Studies Group (ICON) (  22  ); and 
ICON6 (  23  ) (  Table 1  ).         
    STAMPEDE          
  STAMPEDE (  21  ) is a six-arm, five-stage trial of different 
therapies for men who are starting hormone therapy for 
advanced prostate cancer. Such men will typically have disease 
that has spread beyond the prostate, and thus it is standard care 
to treat their disease systemically with hormonal therapy. 
Approximately 85% of patients initially respond well to such 
hormone therapy, but the disease progresses in virtually all 
patients, with a median time to progression of approximately 
      Figure 1    .       Hypothetical randomized 
trial showing a multi-arm, two-
stage design. Arm 1 is the control 
arm and arms 2  –  5 are the experi-
mental arms. At the end of stage I, 
each experimental arm is com-
pared against the control arm in a 
pairwise manner using the inter-
mediate outcome measure (in this 
case, progression-free survival). At 
the end of stage II, each experi-
mental arm that has passed stage I 
is compared with the control arm 
on the primary outcome measure 
for the trial (primary comparison; 
in this case overall survival). How-
ever, secondary comparisons of 
ex    perimental versus control for 
each arm that did not pass stage I 
are also performed (these compari-
sons will, of course, have fewer 
patients and events).       jnci.oxfordjournals.org    JNCI | Commentary 1207
24 months. A number of treatments, when added to hormone 
therapy, could potentially improve these outcomes. STAMPEDE 
is a trial of three of these therapies, together with some combi-
nations of them. 
  In STAMPEDE, patients are randomly assigned to either the 
control arm or one of ﬁ  ve experimental arms (  Figure 3, A  ). The 
ﬁ  ve stages of the trial include a pilot stage, three intermediate 
activity stages, and a ﬁ  nal efﬁ  cacy stage (  Figure 4  ). The randomiza-
tion ratio to the control and the ﬁ   ve experimental arms is 
2:1:1:1:1:1. The control arm is used in all the pairwise compari-
sons, and this imbalance in randomization facilitates a more reli-
able estimate of the event rates in the control arm at any given 
time. Moreover, for a given total number of patients to be ran-
domly assigned to the trial, the imbalance increases the power 
slightly for each pairwise comparison with the control arm.                 
  The pilot phase was planned to include 210 patients, with the 
aim of conﬁ  rming the safety of the ﬁ  ve experimental treatments, 
particularly in the two arms with treatment combinations of 
   
  Figure 2    .       Where do multi-arm multi-stage (MAMS) trials ﬁ  t into the phase 
1, 2, and 3 setup?   A  ) The traditional approach. Three new agents, R1, R2, 
and R3, enter and pass three single-agent single-arm phase 2 trials and 
also three separate single-arm combination phase 2 trials. The three com-
bination therapies are ﬁ  nally compared with the control therapy in three 
separate randomized phase 3 trials. In this model, a total of 2100 patients 
are required.   B  ) In the MAMS design, the single-agent single-arm phase 2 
trials are followed by a single MAMS trial of all combination therapies. 
The MAMS model required 1300 patients in total, a saving of 800 patients. 
C = control arm; R1 = experimental arm R1; R2 = experimental arm R2; 
R3 = experimental arm R3. In these models, we assume that single-agent 
studies would be carried out before combination therapy studies and that 
phase 2 studies require only a small number of centers. Consequently, 
phase 2 studies of different agents may be carried out concurrently. We 
also assume that phase 3 trials require larger numbers of patients and a 
network of centers that can run only one trial in a particular group of 
patients at a time, and, therefore, phase 3 trials of different agents must be 
carried out sequentially. The MAMS design rolls the phase 2 assessment 
of the activity of combination therapy into the same trial as the phase 3 
assessment of effectiveness.       1208   Commentary | JNCI  Vol. 100, Issue 17  |  September 3, 2008
zoledronic acid plus docetaxel and zoledronic acid plus celecoxib 
that had not been tested before in men with prostate cancer. There 
was no a priori reason to suspect that any of the experimental 
treatments would produce unacceptable toxic effects. The three 
intermediate activity stages were designed to compare each experi-
mental arm pairwise with the control arm on the intermediate out-
come measure of failure-free survival (FFS, including prostate-speciﬁ  c 
antigen  –  deﬁ  ned progression). At each of these stages, the guideline 
  Table 1    .       Examples of multi-arm, multi-stage trials (protocols for these trials)  *     
    Trial name Cancer type
Number of 
arms
Number of 
stages Status
Number of companies 
involved   
    STAMPEDE Hormone-naive 
 prostate  cancer
6 5 Open to accrual 3 
  GOG-182/ICON5 Advanced ovarian 
 cancer
5 2 Closed to accrual  —  results 
 publicly  presented
3 
  ICON6 Relapsed ovarian 
 cancer
3 3 Open to accrual 1   
    *     Protocols for these trials are available from the authors on request. STAMPEDE = Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of 
Drug Efficacy; GOG = Gynecologic Oncology Group; ICON = International Collaborative Ovarian Neoplasm studies.     
   
  Figure 3    .       Two multi-arm multi-stage trials.   A  ) Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efﬁ  cacy 
(STAMPEDE) trial with six arms (A  –  F).   B  ) Gynecologic Oncology Group/International Collaborative Ovarian Neoplasm Studies (GOG-182/ICON5) 
trial with ﬁ  ve arms (I  –  V).       jnci.oxfordjournals.org    JNCI | Commentary 1209
critical value has been set for the observed HR. These critical values 
are 1.00, 0.92, and 0.89 for stages I, II, and III, respectively, and 
analyses will be performed when 115, 225, and 355 FFS events, 
respectively, have been observed in the control arm. The ﬁ  nal stage 
has the primary outcome measure of overall survival. Key operating 
characteristics at each stage and overall are the error of continuing 
to the next stage, should the null hypothesis be true, the overall type 
I error, and the power (  Table 2  ). How were the hurdles chosen? 
First, if an experimental arm is as effective as speciﬁ  ed in the alter-
native hypothesis, then we require a high probability that it will 
continue to the next stage. This probability is set at 95% for stages 
I to III inclusive. To achieve this probability and still have an oppor-
tunity to stop an experimental arm for lack of beneﬁ  t, we need to 
take a more “relaxed” approach to continuing to the next stage when 
   
  Figure 4    .        Five Stages of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efﬁ   cacy (STAMPEDE) trial. 
IDMC     =    Independent Data Monitoring Committee; FFS     =    failure-free survival; HR     =    hazard ratio, where 0   ≤   d   ≤   c   ≤   b   ≤   a   ≤   5.       1210   Commentary | JNCI  Vol. 100, Issue 17  |  September 3, 2008
the null hypothesis is true. An error in this direction can be consid-
ered to be “conservative.” For STAMPEDE, at the end of the ﬁ  rst 
stage, we have set a 50% probability of stopping each experimental 
arm when the null hypothesis is true. After the ﬁ  rst stage, as the 
control arm events continue to accumulate and the information in 
the trial increases, this probability can be reduced. Thus, at the end 
of the second stage, the probability of continuing when the null 
hypothesis is true is reduced to 25%, and at the third stage it is 
reduced further, to 10%. The power at the end of stage IV for the 
outcome of overall survival is set at the traditional 90%, with a (one-
sided) type I error of 2.5%. Overall, across all stages, each pairwise 
comparison retains good power of 84%, with an overall type I error 
of 1.7%. The boundaries and probabilities of stopping, assuming we 
were to observe an estimate from the trial exactly on the critical HR 
for that stage, are best displayed graphically (  Figure 5  ).                 
  Using a uniform distribution to model the accrual rate means 
that at the end of these three stages, we anticipate 1200, 1800, and 
2400 patients to be randomly assigned in the entire trial. For each 
experimental arm, these numbers will correspond to 172, 272, and 
392 patients being entered into each arm (remaining) under the 
assumption that ﬁ   ve experimental arms will accrue in the ﬁ  rst 
stage, four in the second, and three in the third. This trial recruited 
its ﬁ  rst patient on October 17, 2005, and is anticipated to be com-
pleted within 7 years. By June 4, 2008, 582 patients had been 
entered. The pilot phase had been completed successfully, and all 
arms had been continued into the next stage.   
    GOG-182/ICON5 
  GOG-182/ICON5 is an MAMS trial with five arms and two 
stages. Women with advanced ovarian cancer were randomly 
  Table 2    .       Design characteristics of the STAMPEDE trial  *     
    Stage
Primary 
outcome
Targeted HR 
(alternative 
hypothesis)
Critical 
HR    †   Error
Power for 
targeted 
difference (%)
Number of 
events required 
in control arm
Expected total 
number of 
patients   
    Pilot Toxicity n/a n/a n/a n/a n/a 210 
  I FFS 0.75 1.00 0.5    ‡   95  § 115 1200 
  II FFS 0.75 0.92 0.25    ‡   95  § 225 1800 
  III FFS 0.75 0.89 0.1    ‡   95  § 355 2400 
  IV OS 0.75 n/a 0.025    ||   90  ¶ 440 3200 
  Overall Pairwise 0.017    ||   84  ¶    
    *     HR = hazard ratio, n/a = not applicable; FFS = failure-free survival; OS = overall survival; STAMPEDE = Systemic Therapy in Advancing or Metastatic 
Prostate Cancer: Evaluation of Drug Efficacy.   
      †       The critical hazard ratio is the guideline critical value such that if the pairwise observed hazard ratio was closer to 1, then consideration would be given 
to discontinue further randomizations to this experimental arm.   
      ‡       An error of this type represents the probability of continuing to the next stage when the null hypothesis (of no difference) for the intermediate outcome 
measure is true.   
    §     These values represent the probability of continuing to the next stage when the alternative hypothesis for the intermediate outcome measure is true.   
      ||       These errors are traditional type I errors. They represent the probability of concluding that there is a difference when the null hypothesis for the primary 
outcome measure is true.   
    ¶     These values represent the “power” in the traditional sense  —  the probability of rejecting the null hypothesis of no difference on the primary outcome 
measure when the alternative hypothesis for the primary outcome measure is true.     
      Figure 5    .        Stopping guidelines on the 
hazard ratio scale for the Systemic Ther-
  apy in Advancing or Metastatic Prostate 
Cancer: Evaluation of Drug Efﬁ  cacy 
(STAMPEDE) trial. CI = conﬁ  dence 
interval; HR = hazard ratio; Stop = stop-
ping of accrual (rather than termination 
of follow up).       jnci.oxfordjournals.org    JNCI | Commentary 1211
assigned to one of five different combination chemotherapy regi-
mens, consisting of four experimental arms and one control arm 
(  Figure 3, B  ). Separate pilot trials (  24    –    26  ) were conducted before 
GOG-182/ICON5, the main aim of which was to confirm the fea-
sibility and safety of the new combination regimens before launch-
ing a randomized controlled trial; activity was not a major outcome 
measure. The first stage analysis of GOG-182/ICON5, using pro-
gression-free survival, was planned when 240 progressions or 
deaths in the control arm had been observed. The second stage of 
the trial was designed to focus on overall survival. At both stages, 
each of the four experimental arms was to be compared in a pair-
wise manner with the control arm. 
  The trial started accruing patients on February 7, 2001, and, 
with an anticipated entry rate of 500 patients per year, the 240 
progressions or deaths were predicted to be observed approxi-
mately 4 years into the trial. At the outset, the guideline critical 
value of the hazard ratio for each pairwise comparison of progres-
sion-free survival after stage I was set at 0.87 (HR < 1 favors the 
experimental over the control arm). Thus, if the observed HR was 
greater than 0.87 (ie, closer to 1.00), then the Data Monitoring 
Committee (DMC) should consider recommending stopping fur-
ther accrual to that particular experimental arm; if HR was less 
than 0.87, then accrual to the arm should be continued. Assuming 
that the experimental regimen was truly effective (ie, that it had a 
real underlying HR of 0.75), then the probability that it would be 
observed to be better than 0.87 was 93%, with a 5% probability 
that the trial would continue inappropriately. 
  The observed accrual rate was exceptionally high, with more 
than 1200 patients per year being entered into the trial worldwide 
over 3 years. The ﬁ  rst stage analysis was triggered in May 2004, 
when 3836 patients had been randomly assigned and 272 events 
(progressions or deaths) had been reported in the control arm. 
Such a fast accrual rate gave the opportunity to relax the interme-
diate hurdle. Thus, the DMC considered not only the hurdle of 
0.87 but also the hurdle of 0.94. This additional hurdle was intro-
duced without knowledge of the results. This change means that if 
an experimental regimen was truly effective (ie, had a real underly-
ing HR of 0.75), then the probability that it would jump this new 
hurdle was greater than 99.9%, with a 5% probability of continu-
ing to the next stage, should the null hypothesis be true. This con-
servative and small change in the hurdle had very little impact on 
the overall power and type I error for the trial as a whole. 
  The statistical report provided to the DMC presented data on 
PFS, toxicity, and deaths due to treatment (  Table 3  ). Overall sur-
vival data were also presented for context, although data for this 
outcome were inevitably limited. In accordance with the prespeci-
ﬁ  ed guidelines, the DMC saw no justiﬁ  cation to extend accrual to 
any of the arms and thus indicated that the trial be closed to 
accrual of further patients. This conclusion was endorsed by the 
International Steering Committee for the trial, and hence accrual 
was closed on September 1, 2004. The mature results on overall 
survival presented in June 2006 [(  22  ),   Table 4  ] conﬁ  rm that the 
decision to not accrue additional patients was a good one.                 
  The GOG-182/ICON5 trial clearly displays the practical 
value of the MAMS design. Unfortunately, none of the new treat-
ment approaches showed enough potential on the intermediate 
outcome measure of progression-free survival to justify continua-
tion to the second and ﬁ  nal stage of accrual. It was more appropri-
ate to focus resources on assessing new approaches. However, we 
obtained reliable answers to these four questions in 3.5 years 
(from start of accrual to the planned ﬁ  rst stage analysis), which is 
considerably faster than we have been able to do before. The 
MAMS nature of the trial saved some 20 years when compared 
with an alternative approach of four consecutive two-arm 
trials each with overall survival as the primary and only outcome 
measure.   
    ICON6          
  ICON6 (  24  ) is a three-arm, three-stage double-blind placebo-
controlled multicenter randomized phase 3 trial for women with 
relapsed ovarian cancer. The three arms of ICON6 are chemo-
therapy alone, chemotherapy plus cediranib given during chemo-
therapy, and chemotherapy plus cediranib during chemotherapy 
and further cediranib alone for a maximum of 18 months. The 
  Table 3    .       Estimated treatment hazard ratios (HRs) for progression-free survival and overall survival (ratio of experimental to control) for 
the first stage analysis of GOG-182/ICON5 presented to the Data Monitoring Committee in May 2004  *     
    Experimental regimen
Progression-free survival Overall survival 
  Crude HR (95% CI) Adjusted HR    †    Crude HR (95% CI)   
    Gemcitabine triplet 0.95 (0.80 to 1.12) 0.96 0.95 (0.73 to 1.23) 
  Doxil triplet 0.94 (0.80 to 1.12) 0.94 1.09 (0.85 to 1.40) 
  Topotecan doublet 1.07 (0.90 to 1.26) 1.04 0.90 (0.69 to 1.16) 
  Gemcitabine doublet 1.01 (0.85 to 1.19) 0.99 1.01 (0.78 to 1.30)   
    *     CI = confidence interval; GOG = Gynecologic Oncology Group; ICON = International Collaborative Ovarian Neoplasm Studies.   
      †       Adjusted for stage (III vs IV), primary disease site (ovary vs extraovarian), age group (<60 vs 60  –  74.9 vs   ≥  75 years) and size of stage III residual disease (  ≤  1 vs >1 cm).     
  Table 4    .       Updated treatment hazard ratios (HRs) for 
progression-free and overall survival (ratio of experimental to 
control) for the first stage analysis of GOG-182/ICON5 presented 
at the American Society of Clinical Oncology in June 2006  *     
    Experimental regimen
Progression-free 
survival Overall survival 
  Crude HR (95% CI) Crude HR (95% CI)   
    Gemcitabine triplet 0.99 (0.88 to 1.11) 0.98 (0.84 to 1.14) 
  Doxil triplet 1.00 (0.89 to 1.12) 0.97 (0.83 to 1.14) 
  Topotecan doublet 1.09 (0.98 to 1.22) 0.07 (0.92 to 1.24) 
  Gemcitabine doublet 1.05 (0.94 to 1.18) 1.04 (0.88 to 1.21)   
    *     CI = confidence interval; GOG = Gynecologic Oncology Group; 
ICON = International Collaborative Ovarian Neoplasm Studies.     1212   Commentary | JNCI  Vol. 100, Issue 17  |  September 3, 2008
primary outcome measure at the three stages are safety at the first 
stage, progression-free survival at the second stage, and overall 
survival at the third stage.     
    Discussion 
  We have proposed the MAMS design as a direct strategic response 
to the pressing need for clinical trials to achieve more reliable 
results more quickly. Key to the use of the design is the principle 
that many potential new therapies need to be tested in similar time 
frames. The MAMS design may be an appropriate alternative to the 
traditional phase 2 followed by phase 3 trial setting in certain situ-
ations (  Box 1  ). Our approach has two distinguishing characteristics: 
we compare many new therapies at once against a control treatment 
and reject insufficiently active therapies on the basis of an interme-
diate outcome measure in a randomized pairwise comparison with 
the control. This “unified” approach gains its speed from the fact 
that many therapies are considered at the same time and that there 
is a planned and seamless move from one stage to the next. The 
reliability of this design stems from the use of an appropriately 
powered randomized comparison on an intermediate outcome 
measure. The GOG-182/ICON5 trial clearly shows the practical 
value of MAMS trials. With three real examples, we hope that we 
have shown that such trials are feasible and can lead to major 
improvements in speed and decision making. 
  Multi-arm, single-stage trials are not new  —  many such trials 
have been performed in different diseases in different parts of the 
world (  27    –    29  ). Although such trials might initially appear complex 
particularly to patients, clinicians, competent authorities, ethics 
committees, and trial oversight committees, concerns about the 
feasibility of recruitment to such trials have not been realized. In 
STAMPEDE, a two-part patient information sheet was used to aid 
in the understanding of the design. Patients were provided with a 
summary of the trial and its arms at the beginning and were given 
more detailed information about their particular arm after random 
assignment. This “two-stage” informed consent process is in the 
process of being adopted more widely for more conventional trials 
by ethics committees in the United Kingdom. 
  The multi-stage component adds a number of staging posts at 
which accrual to each of the experimental arms can potentially be 
stopped when there is good evidence that the experimental arm is 
unlikely to be clinically better than the control arm. In other areas, 
this may be understood as a stopping guideline for “futility.” 
Again, this is not a new principle, except that we propose using an 
intermediate outcome measure that allows us to screen out ineffec-
tive therapies. In situations for which an intermediate outcome 
measure may not be available, it may be possible to use the primary 
outcome measure measured earlier in time. Such an alternative 
approach is similar to the approach proposed by Simon et al. (  30  ). 
  The intermediate outcome measure does not need to be a surro-
gate for the primary outcome measure. It does need to be related in 
the sense that if a new treatment has little or no effect on the inter-
mediate outcome measure, then it will likely have little or no effect on 
the primary outcome measure. Importantly, however, this relation-
ship does not have to apply in the other direction. Thus, we do not 
assume that just because an effect has been observed on the interme-
diate outcome measure that we shall see an effect on the primary out-
come measure. Good examples of intermediate and ﬁ  nal outcomes 
are progression-free survival and overall survival, respectively. 
  From one point of view, the early stages of the design (at which 
the intermediate outcome measure is being used) could be viewed 
as a set of simultaneous well-designed comparative randomized 
phase 2 trials. The main difference is that there is a formal random-
ized comparison that is appropriately powered and designed to 
inform stop/go decisions, in contrast to the traditional nonrandom-
ized comparisons that are made in the conventional testing of new 
therapies. At these early stages, the probability of continuing to the 
next stage should the alternative hypothesis be true should remain 
high  —  we have typically used 95%. To achieve this high probabil-
ity, the probability of continuing to the next stage should the 
null hypothesis be true is relaxed  —  we have used 10% to 50%. 
This probability can get progressively smaller as the information 
(number of events) increases, the STAMPEDE trial is a good exam-
ple. The type I error over the trial is protected by the fact of the 
need to jump each staged hurdle. The likelihood of an ineffective 
therapy passing through all intermediate stages and the ﬁ  nal stage 
is small indeed. This component of the design can be considered to 
provide a seamless transition from phase 2 (earlier stages of the 
trial) to phase 3 (ﬁ  nal stage), with all patients involved in the earlier 
stages contributing to the ﬁ  nal stage, and as such has similarities to 
other seamless phase 2/3 designs. A review of these types of designs 
and their application has been provided by Schmidli et al. (  31  ). 
  The two components of the MAMS design can be used sepa-
rately. For example, a staged design could be used in a two-arm 
trial, which would be more efﬁ  cient than a traditional two-arm 
trial. Thus, the trial design would allow for early stopping for futil-
ity. Alternatively, a multi-arm trial could be performed with only 
  Box 1.     Summary of when a multi-arm, multi-stage (MAMS) trial 
may be useful. 
      A MAMS design may be useful when:               
  1)       Many new approaches (therapies/regimens) are available for 
evaluation in phase 2/3 trials:               
  i)     that have sufficient promise to warrant investigation           
  ii)     that can be distributed widely                                     
  2)       There is no a priori reason to expect one approach to be 
better than another            
  3)       There is an intermediate outcome measure that is correlated 
with the primary outcome measure (the primary outcome 
may serve as an intermediate outcome measure if it can be 
measured at several time points) such that:               
  i)       If there is little or no impact of an experimental arm on 
the intermediate outcome, there is likely to be little or no 
impact on the primary outcome.            
  ii)       If the intermediate and primary outcome measures are 
measured on the same scale, then, if the alternative hypoth-
esis is true on the primary outcome, the alternative hypoth-
esis (or something more extreme) is also likely to be true for 
the intermediate outcome measure.                                     
  4)       There are sufficient funds to support a more complex MAMS 
trial            
  5)       The accrual rate can support an MAMS trial                   jnci.oxfordjournals.org    JNCI | Commentary 1213
one stage. Although both may give some beneﬁ  ts, they do not reap 
the full beneﬁ  ts of the MAMS trial. 
  This MAMS design also forces those who are designing new 
trials to think more strategically beyond the question of “We have 
a promising new compound, can it improve outcomes for patients 
with disease x?” to “How can we plan to improve outcomes for 
patients with disease x as swiftly and reliably as possible?” The ﬁ  rst 
question would perhaps lead to a traditional large-scale two-arm 
phase 3 trial, whereas the latter should lead to widespread consid-
erations of the different experimental arms available at any given 
time. As such, this design may be particularly pertinent to research-
ers and agencies in the public sector. There are also advantages in 
the ﬂ  exibility allowed by such designs. For example, different arms 
do not necessarily need to include different agents; they could 
explore different durations or doses of a new agent, such as in 
ICON6  —  a three-arm, three-stage trial of the new targeted agent 
cediranib. This approach may be particularly important for such 
targeted agents for which the optimal duration or dose of therapy 
is often unclear when initiating phase 3 trials. 
  The MAMS design is not without potential drawbacks. 
Although the trial itself may be of shorter duration, it may take 
longer to set up. A contributing factor is the greater deal of com-
plexity that arises when drugs may have to be sourced from differ-
ent companies. Perhaps surprisingly, industry partners have been 
supportive of this design, even when it puts their agent into the 
same trial as a competitor’s. Strategies that we have used to per-
suade industry partners to include their agents in such trials are as 
follows. First, it would be to the company’s detriment if their 
product was not included and a promising agent from another 
company may take its place. Second, the MAMS design does not 
compare “head-to-head” the various products from different com-
panies; each experimental arm is compared formally only against 
the control arm, and this is not dissimilar to running separate two-
arm trials. It is possible that all of the experimental therapies will 
prove successful, and there may be an opportunity to further 
improve outcomes by looking at combinations of the experimental 
therapies. Finally, the design is a form of risk management for the 
company (and the investigators). If an experimental therapy is 
unlikely to prove beneﬁ  cial, then it is better to stop investing fur-
ther patients, time, and money in testing it. The three examples 
show that these approaches have been successful with a wide range 
of drugs from a number of companies. 
  In certain situations  —  for example, when more than one of the 
experimental arms continues to the ﬁ  nal stage  —  then MAMS trials 
will need to be considerably larger than standard two-arm trials. 
Such large trials will often require cooperative groups to undertake 
them and further may require international collaborations. Despite 
aims to improve the harmonization of the regulatory environment 
(  32  ,  33  ), international collaborations are complex to initiate and 
undertake. It is also unlikely that individual pharmaceutical com-
panies will have more than one product that they are willing to test 
in a particular setting at any given time. All of these issues mean 
that MAMS trials are likely to be possible only in cooperative 
groups. These groups do, however, undertake a large proportion 
of the large-scale cancer trials. Software that is available from Stata 
has been developed to help design MAMS trials and may be 
obtained from the authors upon request.   
  Our hope is that others will exploit the opportunities that the 
MAMS trial design offers to correspondingly speed up the assess-
ment and introduce new therapies to patients with a wide range of 
cancers, and also more broadly in other diseases.         
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